Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension

Year of Publication: 2020
Contained in: Emerging microbes & infections Vol. 9, No. 1 (2020), p. 757-760
All journal articles: Search for all articles in this journal
Language: English
Contributors: Meng, Juan | Author
Xiao, Guohui
Zhang, Juanjuan
He, Xing
Ou, Min
Bi, Jing
Yang, Rongqing
Di, Wencheng
Wang, Zhaoqin
Li, Zigang
Gao, Hong
Liu, Lei
Zhang, Guoliang
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 9007-41-4
COVID-19
IL6 protein, human
Letter
Renin-angiotensin system
angiotensin II type1 receptor blockers
angiotensin-converting enzyme inhibitors
hypertension
Additional Keywords: *Renin-Angiotensin System
Aged
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Betacoronavirus
C-Reactive Protein
CD3 Complex
CD8-Positive T-Lymphocytes
China
Coronavirus Infections
Female
Humans
Hypertension
Interleukin-6
Male
Middle Aged
Pandemics
Pneumonia, Viral
Retrospective Studies
Treatment Outcome
Viral Load
ISSN: 2222-1751
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 02.04.2020
Date Revised 28.04.2020
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1080/22221751.2020.1746200
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04792nma a2201093 c 4500
001 NLM308984285
003 DE-601
005 20200428214631.0
007 cr uuu---uuuuu
008 200405s2020 000 0 eng d
024 7 |a 10.1080/22221751.2020.1746200  |2 doi 
028 5 2 |a pubmed20n1182.xml 
035 |a (DE-599)NLM32228222 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Meng, Juan 
245 1 0 |a Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 02.04.2020 
500 |a Date Revised 28.04.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension 
611 2 7 |a Letter  |2 gnd 
653 2 |a Aged  |6 D000368 
653 2 |a Angiotensin II Type 1 Receptor Blockers  |6 D047228  |a *therapeutic use  |6 Q000627 
653 2 |a Angiotensin-Converting Enzyme Inhibitors  |6 D000806  |a *therapeutic use  |6 Q000627 
653 2 |a Antihypertensive Agents  |6 D000959  |a *therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a C-Reactive Protein  |6 D002097  |a analysis  |6 Q000032 
653 2 |a CD3 Complex  |6 D017252 
653 2 |a CD8-Positive T-Lymphocytes  |6 D018414  |a cytology  |6 Q000166 
653 2 |a China  |6 D002681 
653 2 |a Coronavirus Infections  |6 D018352  |a *complications  |6 Q000150  |a drug therapy  |6 Q000188 
653 2 |a Female  |6 D005260 
653 2 |a Humans  |6 D006801 
653 2 |a Hypertension  |6 D006973  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188  |a virology  |6 Q000821 
653 2 |a Interleukin-6  |6 D015850  |a blood  |6 Q000097 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *complications  |6 Q000150  |a drug therapy  |6 Q000188 
653 2 |a *Renin-Angiotensin System  |6 D012084 
653 2 |a Retrospective Studies  |6 D012189 
653 2 |a Treatment Outcome  |6 D016896 
653 2 |a Viral Load  |6 D019562 
655 7 |a COVID-19  |2 gnd 
655 7 |a Renin-angiotensin system  |2 gnd 
655 7 |a angiotensin II type1 receptor blockers  |2 gnd 
655 7 |a angiotensin-converting enzyme inhibitors  |2 gnd 
655 7 |a hypertension  |2 gnd 
655 7 |a Angiotensin II Type 1 Receptor Blockers  |2 gnd 
655 7 |a Angiotensin-Converting Enzyme Inhibitors  |2 gnd 
655 7 |a Antihypertensive Agents  |2 gnd 
655 7 |a CD3 Complex  |2 gnd 
655 7 |a IL6 protein, human  |2 gnd 
655 7 |a Interleukin-6  |2 gnd 
655 7 |a C-Reactive Protein  |2 gnd 
655 7 |a 9007-41-4  |2 gnd 
689 0 0 |A f  |a Letter 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Renin-angiotensin system 
689 1 2 |a angiotensin II type1 receptor blockers 
689 1 3 |a angiotensin-converting enzyme inhibitors 
689 1 4 |a hypertension 
689 1 |5 DE-601 
689 2 0 |a Angiotensin II Type 1 Receptor Blockers 
689 2 1 |a Angiotensin-Converting Enzyme Inhibitors 
689 2 2 |a Antihypertensive Agents 
689 2 3 |a CD3 Complex 
689 2 4 |a IL6 protein, human 
689 2 5 |a Interleukin-6 
689 2 6 |a C-Reactive Protein 
689 2 7 |A r  |a 9007-41-4 
689 2 |5 DE-601 
700 1 |a Xiao, Guohui 
700 1 |a Zhang, Juanjuan 
700 1 |a He, Xing 
700 1 |a Ou, Min 
700 1 |a Bi, Jing 
700 1 |a Yang, Rongqing 
700 1 |a Di, Wencheng 
700 1 |a Wang, Zhaoqin 
700 1 |a Li, Zigang 
700 1 |a Gao, Hong 
700 1 |a Liu, Lei 
700 1 |a Zhang, Guoliang 
773 0 8 |i in  |t Emerging microbes & infections  |g Vol. 9, No. 1 (2020), p. 757-760  |q 9:1<757-760  |w (DE-601)NLM249572478  |x 2222-1751 
856 4 1 |u http://dx.doi.org/10.1080/22221751.2020.1746200  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 9  |j 2020  |e 1  |b 28  |c 12  |h 757-760